Dr. Advani on EPOCH-R in B Cell Lymphoma

Ranjana Advani, MD
Published: Wednesday, Mar 27, 2013

Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, details the difference between EPOCH-R and R-CHOP chemotherapy.

Dose-adjusted EPOCH-R is an infusion chemotherapy that uses similar drugs to R-CHOP. In preliminary data, patients overcame poor prognostic significance of Bcl-2 overexpression.

While the results of upcoming trials will give more information, Advani says, dose-adjusted EPOCH-R has become the standard of care in patients with primary mediastinal B-cell lymphoma. In this disease, treatment with R-CHOP usually requires radiotherapy as well but with EPOCH-R alone, cure rates are well above 90% and no radiotherapy is needed.

Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, details the difference between EPOCH-R and R-CHOP chemotherapy.

Dose-adjusted EPOCH-R is an infusion chemotherapy that uses similar drugs to R-CHOP. In preliminary data, patients overcame poor prognostic significance of Bcl-2 overexpression.

While the results of upcoming trials will give more information, Advani says, dose-adjusted EPOCH-R has become the standard of care in patients with primary mediastinal B-cell lymphoma. In this disease, treatment with R-CHOP usually requires radiotherapy as well but with EPOCH-R alone, cure rates are well above 90% and no radiotherapy is needed.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Hematology Briefings™: Advancing Care and Improving Outcomes for Patients With Pyruvate Kinase DeficiencyOct 31, 20181.0
Publication Bottom Border
Border Publication
x